Our Unique Story

Gritstone is developing targeted immunotherapies for cancer and infectious diseases. Gritstone’s approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens, and more recently extended our programs to include viral antigens displayed on the surface of virally infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients. To learn more about Gritstone's approach, please view the video below.

Meet Gritstone

Gritstone is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts and Pleasanton, California. We were founded in August 2015 and are listed on the Nasdaq Global Select Market under the ticker symbol GRTS.

Our Leadership

To deliver on the promise of our novel therapeutic approaches, we have assembled an experienced leadership team with deep expertise in each of our core disciplines of immunotherapy research, genomics and bioinformatics, clinical and regulatory development, and biomanufacturing.

View Bio
Andrew Allen, M.D., Ph.D.

Co-founder, President and Chief Executive Officer

View Bio
Celia Economides

Executive Vice President and Chief Financial Officer

View Bio
Matthew Hawryluk, Ph.D.

Executive Vice President and Chief Business Officer

View Bio
Erin E. Jones, M.S.

Chief Operating Officer

View Bio
Karin Jooss, Ph.D.

Head of Research & Development

View Bio
Stacy Proctor

Senior Vice President and Head of People

View Bio
Rahsaan W. Thompson, J.D.

Executive Vice President and General Counsel

View Bio
Vijay Yabannavar, Ph.D.

Executive Vice President and Chief Technical Development Officer

of Directors

Shefali Agarwal, M.D., M.P.H.
Executive Vice President, Chief Medical and Development Officer at Epizyme
Andrew Allen, M.D., Ph.D.
Co-founder, President and Chief Executive Officer
Lawrence Corey, M.D.
Former President and Director, Fred Hutchinson Cancer Research Center
Clare Fisher
SVP of Business Development and Mergers & Acquisitions at BeiGene
Elaine V. Jones, Ph.D.
Steve Krognes
Chief Financial Officer of Denali Therapeutics
Naiyer A. Rizvi, M.D.
Chief Medical Officer at Synthekine

Advisory Board

Timothy A. Chan, M.D., Ph.D.
James L. Gulley, M.D., Ph.D.
Graham Lord, M.D., Ph.D.
Naiyer A. Rizvi, M.D.
Alessandro Sette, Dr.Biol.Sci.
Eugene Zhukovsky, Ph.D.